NeOnc Technologies (NTHI) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed NeOnc Technologies (NTHI) over the past year, gaining 2.0% versus a loss of 79.1%. PDS Biotechnology is the larger company by market cap ($89.5 million vs $79.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | PDSB |
|---|---|---|
| Share price | $2.76 | $1.24 |
| Market cap | $79.50M | $89.51M |
| 1-day change | +9.08% | +21.08% |
| YTD return | -69.41% | +32.47% |
| 1-year return | -79.07% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-2.13 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $1.55 |
| 52-week low | $2.50 | $0.195 |
| Distance from 52-week high | -77.17% | -20.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +515.99% | +304.86% |
| Average volume | 195.17K | 23.24M |
| Shares outstanding | 28.81M | 72.47M |
| Employees | 5 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed NTHI by 81.1 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NTHI vs PDSB FAQ
Which is bigger, NeOnc Technologies or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $89.51M compared with $79.50M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.